The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors
NCT02282059
·
clinicaltrials.gov ↗
COMPLETED
Status
100
Enrollment
INDUSTRY
Sponsor class
Conditions
Pancreatic Neuroendocrine Tumors
Interventions
DRUG:
sunitinib
Sponsor
Pfizer